Salivary Melatonin Profile Interpretation by Decade of Life

What the Salivary Melatonin Profile Actually Measures

A salivary melatonin profile is not a single fasting blood draw. It is a time-series assay: the patient collects saliva at four to six standardized intervals under dim-light conditions, typically from 6 PM through midnight or 2 AM. Each sample is analyzed by enzyme-linked immunosorbent assay (ELISA) or liquid chromatography-mass spectrometry (LC-MS/MS), with LC-MS/MS offering lower detection limits near 0.5 pg/mL.

The DLMO Metric and Why It Outranks a Single Peak Value

The single most clinically informative number from the profile is the dim-light melatonin onset (DLMO), defined as the clock time at which salivary melatonin first exceeds a threshold of 3 pg/mL (or sometimes 4 pg/mL depending on the laboratory). DLMO anchors the entire circadian clock. It predicts sleep onset latency better than subjective bedtime, correlates with cortisol awakening response the following morning, and can identify circadian phase disorders invisible to standard polysomnography. A 2018 review in the Journal of Biological Rhythms confirmed that DLMO derived from saliva closely tracks DLMO derived from plasma, with a mean offset of less than 25 minutes.

Dim-Light Protocol: The Non-Negotiable Variable

Light is the primary suppressor of melatonin synthesis via the retinohypothalamic tract. Ambient light above 10 lux during the collection window will suppress melatonin and falsely lower every data point in the profile. Patients must wear blue-light-blocking glasses or remain in a <10 lux environment from the first sample through the last. Standard overhead LED lighting registers 100 to 300 lux. A study by Brainard et al. Published in the Journal of Neuroscience established that even 10 minutes of 200-lux exposure suppresses salivary melatonin by up to 50% within the collection window. (Brainard GC et al., J Neurosci 2001)

Normal Ranges by Decade of Life

Melatonin production is not static across the lifespan. The pineal gland reaches peak synthetic capacity in children ages 1 to 3, then declines sharply through adolescence before stabilizing in young adulthood. After age 40, a second, more gradual decline begins. Understanding where a patient falls relative to their own age cohort changes clinical decision-making significantly.

Ages 20 to 29: The Physiologic Peak

Adults in their twenties typically show nocturnal salivary melatonin peaks between 80 and 120 pg/mL, with DLMO occurring between 9:00 PM and 10:00 PM in individuals with regular schedules. A seminal study by Zeitzer et al. (N=15, mean age 24) published in the American Journal of Physiology found mean peak salivary melatonin of 92 pg/mL in young adults under controlled dim-light conditions. Total area under the melatonin curve (AUC) across the night is highest in this decade. Phase delay is common: students and shift workers in their 20s frequently show DLMO as late as 11:30 PM, which is a phase disorder rather than a normal variant.

Ages 30 to 39: Stable But Beginning to Stratify

Mean nocturnal peaks in the 30s run 70 to 110 pg/mL, still overlapping with the 20s cohort. DLMO timing is similar (9:00 to 10:30 PM), but total AUC begins to drop as melatonin clearance accelerates slightly with rising liver CYP1A2 enzyme activity. Parenthood, shift work, and high artificial-light exposure during these years can suppress DLMO by 45 to 90 minutes compared to age-matched controls with low light exposure. (Gooley JJ et al., J Clin Endocrinol Metab 2011)

Ages 40 to 49: The First Clinically Significant Drop

The 40s represent the decade when pineal calcification accelerates and melatonin output begins a measurable decline. Expected nocturnal peaks fall to 50 to 90 pg/mL. Patients in this decade who present with insomnia onset, mood changes, or early waking frequently show profiles in the 25 to 45 pg/mL range, well below their age-cohort mean. DLMO may advance by 30 to 60 minutes compared to younger years, an early marker of the circadian phase advance that becomes pronounced after 60. A cross-sectional study of 209 adults published in the Journal of Clinical Endocrinology and Metabolism documented a mean 13.5% reduction in urinary melatonin metabolites (6-OHMS) per decade beginning at age 40. (Zhao ZY et al., J Clin Endocrinol Metab 2002)

Ages 50 to 59: Perimenopause, Andropause, and Compounding Decline

Two hormonal transitions converge in this decade: declining estradiol in women and declining testosterone in men. Both sex steroids modulate pineal arylalkylamine N-acetyltransferase (AANAT) activity, the rate-limiting enzyme for melatonin synthesis. Expected nocturnal salivary melatonin falls to 30 to 70 pg/mL. Patients in surgical menopause show steeper declines, sometimes reaching 15 to 25 pg/mL even in their early 50s. A 2014 study in Menopause (N=102) found that postmenopausal women had significantly lower DLMO amplitude compared to premenopausal controls matched for age and BMI (P<0.001).

Ages 60 to 69: Reference Ranges Officially Narrow

By the 60s, expected nocturnal peaks in healthy, light-controlled conditions range from 20 to 50 pg/mL. What changes equally is DLMO timing: phase advance of 60 to 90 minutes relative to young adults is typical, meaning patients fall asleep earlier and wake earlier involuntarily. "Early morning awakening in older adults is largely a circadian phase advance rather than a sleep maintenance disorder," according to Dr. Charles Czeisler's group at Harvard, whose work on age-related circadian changes has been foundational. (Czeisler CA et al., Science 1999) A result of 30 pg/mL in a 65-year-old is within the age-specific reference range but is not optimal by longevity-medicine standards.

Ages 70 and Beyond: When Single-Digit Peaks Appear

In adults over 70, nocturnal salivary melatonin peaks of 10 to 30 pg/mL are common. Some individuals over 80 show peaks <5 pg/mL. These single-digit results are associated with increased fall risk, cognitive decline, and all-cause mortality in several longitudinal cohorts. A 2023 study published in JAMA Network Open (N=1,016, mean age 74) reported that participants in the lowest quartile of urinary 6-OHMS (the primary melatonin metabolite) had a 28% higher rate of incident dementia over 8 years compared to those in the highest quartile. (Leng Y et al., JAMA Netw Open 2023) Phase coherence also deteriorates: the melatonin profile shape flattens, losing the sharp nocturnal rise and fall that defines healthy circadian rhythmicity.

What "Optimal" Means Versus "Reference Range Normal"

Reference ranges on most laboratory reports are defined statistically as the central 95th percentile of a tested population. That population typically includes people with obesity, irregular sleep schedules, and high artificial-light exposure. "Normal" in that context is a low bar.

The Longevity-Medicine Distinction

In longevity-medicine and functional endocrinology practice, optimal targets differ from population-normal ranges by approximately one standard deviation toward higher amplitude and earlier DLMO. The HealthRX clinical framework defines the following optimal salivary melatonin targets for adults on no exogenous melatonin:

| Age Decade | Optimal Nocturnal Peak (pg/mL) | Optimal DLMO Time | Flag for Review | |---|---|---|---| | 20 to 29 | 90 to 120 | 9:00 to 10:00 PM | <60 or DLMO after 11 PM | | 30 to 39 | 75 to 110 | 9:00 to 10:30 PM | <50 or DLMO after 11:30 PM | | 40 to 49 | 55 to 90 | 9:00 to 10:30 PM | <35 or DLMO after 11:30 PM | | 50 to 59 | 40 to 70 | 9:15 to 10:30 PM | <25 or DLMO after 11 PM | | 60 to 69 | 30 to 55 | 9:00 to 10:15 PM | <20 or DLMO after 10:30 PM | | 70+ | 20 to 40 | 8:30 to 10:00 PM | <10 or absent nocturnal rise |

These thresholds are derived from published studies correlating melatonin amplitude with sleep efficiency, metabolic health markers, and cognitive performance rather than from the statistical distribution of a convenience sample.

DLMO Phase vs. Amplitude: Two Separate Problems

A profile can be low-amplitude with normal phase, or phase-delayed with near-normal amplitude. These require different interventions. Low amplitude with normal phase suggests pineal insufficiency or excessive light suppression and may respond to low-dose exogenous melatonin (0.5 to 1 mg taken 60 to 90 minutes before the measured DLMO). Phase delay with preserved amplitude suggests circadian rhythm disorder and responds better to timed bright-light therapy (10,000 lux for 30 minutes at target wake time) combined with strict sleep scheduling. A randomized controlled trial by Burgess et al. (N=36) demonstrated that morning bright-light therapy advanced DLMO by a mean of 1.5 hours over 4 weeks without changing peak melatonin amplitude.

Factors That Distort the Profile Independent of Age

Medications That Suppress Melatonin

Beta-blockers are the most commonly overlooked melatonin suppressors. Propranolol and atenolol inhibit beta-1 adrenergic signaling that drives pineal AANAT activity, reducing nocturnal melatonin output by 20 to 50% depending on dose and timing. A controlled study published in the British Journal of Clinical Pharmacology (N=22) showed propranolol 80 mg at night reduced salivary melatonin AUC by 39% compared to placebo. NSAIDs, benzodiazepines, and selective serotonin reuptake inhibitors (SSRIs) at high doses also reduce melatonin output, though the magnitude is smaller.

Body Weight and Insulin Resistance

Adipose tissue expresses CYP1A2, the primary melatonin-clearing enzyme. Individuals with BMI above 35 clear melatonin faster, producing shorter and lower-amplitude nocturnal profiles even when pineal synthesis is intact. Insulin resistance independently blunts the DLMO response. A 2021 analysis from the HERITAGE Family Study found that participants with fasting insulin above 15 mIU/L had DLMO profiles with 18% lower peak amplitude than insulin-sensitive controls matched for age and sex. (Wolff CA et al., Proc Natl Acad Sci 2020)

Shift Work and Travel

Transmeridian travel and rotating shift schedules produce profiles that cannot be interpreted against standard clock-time references. For shift workers, DLMO must be interpreted relative to habitual sleep onset, not local time. The Society for Research on Biological Rhythms recommends collecting a minimum of two profiles 4 weeks apart before making a clinical decision in anyone with irregular schedules.

How to Use the Profile to Guide Clinical Action

When to Retest Before Intervening

A single low-amplitude profile collected without strict protocol adherence carries a high false-positive rate. If the patient used a smartphone within 30 minutes of any sample, drank caffeinated beverages after 2 PM, or exercised within 3 hours of the first sample, the result should be repeated. Caffeine slows melatonin clearance but simultaneously advances DLMO; the net effect on amplitude is variable and sample-dependent.

Low-Dose Melatonin: Dose Matters More Than Timing

Most over-the-counter melatonin products range from 3 to 10 mg per dose, a quantity that produces pharmacological plasma levels 10 to 100 times above physiological nocturnal peaks. Physiological replacement in an adult with a nocturnal peak of 15 pg/mL means starting at 0.3 to 0.5 mg, not 5 mg. A dose-finding study by Brzezinski et al. (N=30) found that 0.3 mg of oral melatonin produced plasma levels closely matching normal young-adult nocturnal peaks, whereas 3 mg produced supraphysiological levels that desensitized MT1/MT2 receptors over 4 weeks. Prolonged exposure to supraphysiological melatonin doses may suppress endogenous synthesis, though evidence for this in humans remains incomplete.

Timed Administration by Profile Result

• Low amplitude, normal DLMO: Give 0.3 to 0.5 mg melatonin 60 minutes before measured DLMO time.
• Phase delay (DLMO after 11 PM), any amplitude: Morning bright light (10,000 lux, 30 min at target wake time) is first-line. Add 0.5 mg melatonin 5 hours before target sleep onset if bright light alone fails after 3 weeks.
• Phase advance (DLMO before 8:30 PM in under-60 adults): Evening bright light exposure from 7 to 9 PM, avoid morning light until after 8 AM.
• Flat profile (<5 pg/mL throughout), no identifiable medication cause: Refer for pituitary and pineal imaging if under 50. In adults over 70, flat profiles may reflect irreversible pineal calcification; prioritize sleep hygiene, light therapy, and review of melatonin-suppressing medications.

Collecting a Salivary Melatonin Profile: Step-by-Step

Accurate collection determines whether the result is interpretable. Patients who follow these steps exactly produce profiles with less than 8% coefficient of variation between repeat collections.

What to Do the Day of Collection

Avoid alcohol entirely. Stop any exogenous melatonin 5 full days before the collection day. Eat dinner before 7 PM to avoid oral fluid contamination from food. Begin wearing blue-light-blocking glasses (transmittance <1% at 450 to 480 nm) at 6 PM. Set an 8 PM reminder to turn off overhead lights and switch to amber or candlelight-equivalent lamps (<10 lux at eye level).

Sample Timing and Handling

Collect each sample by passive drool into a polypropylene tube. Standard protocols space samples every 30 to 60 minutes beginning at 6:00 PM, with the final sample at midnight. Do not eat, drink anything other than water, or brush teeth within 30 minutes of any sample. Freeze all samples within 1 hour of the last collection or refrigerate at 4°C if shipping same-day. Melatonin degrades by approximately 15% over 48 hours at room temperature. (Voultsios A et al., J Clin Endocrinol Metab 1997)

Special Populations: Pregnancy, Autism Spectrum, and Night-Shift Workers

Pregnancy

Salivary melatonin peaks rise substantially in the third trimester, driven by placental melatonin synthesis. Reference ranges established in non-pregnant populations do not apply. Nocturnal peaks of 150 to 200 pg/mL in the third trimester are normal and reflect fetal circadian programming rather than maternal hypersecretion. (Reiter RJ et al., Fertil Steril 2014)

Autism Spectrum Disorder

Children and adolescents with autism spectrum disorder (ASD) frequently show DLMO delays of 2 to 3 hours beyond age-matched neurotypical peers, even when light exposure is controlled. The MTNR1B and ASMT gene variants common in ASD reduce both melatonin synthesis and receptor sensitivity. Low-dose melatonin (1 to 3 mg, 30 to 60 minutes before target sleep onset) is one of the few pediatric sleep interventions with randomized controlled trial evidence. A Cochrane review by Bruni et al. (2022) covering 8 RCTs (N=541 children) found melatonin reduced sleep-onset latency by a mean of 37 minutes versus placebo in children with ASD (P<0.001).

Night-Shift Workers

Chronic night-shift workers often show a completely inverted profile: melatonin peaks during daytime sleep rather than biological night. Interpreting these profiles requires knowing the patient's current work schedule and habitual sleep window. A profile showing "normal" daytime peaks in a night-shift worker actually represents proper adaptation; the clinical concern is the worker who shows blunted peaks at both daytime and nighttime, suggesting total circadian fragmentation. The American Academy of Sleep Medicine guidelines on shift-work disorder recommend using DLMO relative to habitual sleep onset rather than clock time as the primary interpretive reference point.